Refine search

Date
Tumour Site
Topics
Congress

146 results for ""

The tipping point of cancer biomarker quality

The tipping point of cancer biomarker quality

Too often the access to quality biomarkers is undermined by poor knowledge on the need for quality assurance. Relying on the assumption that biomarkers bring ‘innovation’ without claiming quality may be appealing to some, perhaps not really to medical conservatives – and not to patients, for sure. 

    By
  • Dario Trapani
Novel approaches to improve immunotherapy and more news on synthetic lethality

Novel approaches to improve immunotherapy and more news on synthetic lethality

The ESMO Congress 2021 has started today with three sessions on developmental therapeutics, including immunotherapy. The overarching theme in these sessions is the improvement of checkpoint inhibitor-based immunotherapy and a new flavour of synthetic lethality in molecularly pre-defined solid tumours.

    By
  • Markus Joerger

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.